Searchable abstracts of presentations at key conferences in endocrinology

ea0063p516 | Calcium and Bone 2 | ECE2019

Immobilization induced hypercalcemia

Koseoğlu Derya , Helvacı Nafiye

Introduction: Immobilization induced hypercalcemia, which was first described in 1941 by Albright, is an uncommon reason for hypercalcemia. It is associated with increased bone remodeling disorders and conditions associated with limited movement such as medullar lesions or vascular events. The exact mechanism of the disorder is unknown. Diagnosis requires an detailed evaluation to rule out other causes of hypercalcemia.Case presentation: A 24 year old ma...

ea0070ep320 | Pituitary and Neuroendocrinology | ECE2020

Lateralized sixth cranial nerve palsy after inferior petrosal sinus sampling

Helvacı Burçak , Houssein Mehdi , Dilek Dellal Fatma , Yuce Gokhan , Burçak Polat Şefika , Ersoy Reyhan

Introduction: Inferior petrosal sinus sampling (IPSS) is the gold standard test to differentiate Cushing’s disease from ectopic Cushing syndrome. IPSS may cause severe complications; however, overall rates are low. Subarachnoid hemorrhage (SAH) has been rarely reported after IPSS. Here we report a case who developed hypertensive emergency, left 6th cranial nerve palsy, and SAH after IPSS.Case: A sixty-two years-old female patient had a history of h...

ea0081p515 | Late-Breaking | ECE2022

Parathormone washout in cytology of Suspicious for Follicular Neoplasm

Durmaz Himmet , Cavnar Helvacı Burcak , Beştepe Nagihan , Aksoy Altınboğa Ayşegul , Dirikoc Ahmet , Topaloglu Oya , Ersoy Reyhan , Cakir Bekir

Introduction: The risk of malignancy in thyroid nodules is reported by the Bethesda system by performing fine needle aspiration biopsy (FNAB). Atypia of undetermined significance(AUS) or follicular lesion of undetermined significance(FLUS)(Bethesda 3) and suspicious for a follicular neoplasm (Bethesda 4) create uncertainty about treatment and follow-up. Molecular tests, ultrasonographic features of the nodules, and calcitonin level help us for this uncertainty. Here, we will p...

ea0073aep894 | Late Breaking | ECE2021

Radioactive iodine therapy with recombinant human TSH (rhTSH) for well-differentiated thyroid cancer had no difference in GO outcome; case report

Faki Sevgul , Deniz Serdar , Burçak Cavnar Helvacı , Çağlar Keskin , Burçak Polat , Nilay Yüksel , Şeyda Türkölmez , Oya Topaloğlu , Ersoy Reyhan , BekirÇakir

BackgroundThe risk of cancer is relatively higher in Graves’ patients presenting simultaneously with thyroid nodules. Radioiodine (RAI) therapy recommended in intermediate-high risk differentiated thyroid carcinoma may be associated with worsening of a pre-existing Graves’ orbitopathy (GO) or developing a new onset. The impact of RAI therapy in patients with differentiated thyroid cancer on the course of a pre-exisiting GO has not been specific...